Hypofractionated regimen of precision radiotherapy was not inferior to conventional RT in patients with intermediate-risk prostate cancer.
F-18-fluciclovine PET helps detect and localize recurrent prostate cancer allowing for individualized, targeted therapy.
A single 19-Gy fraction of brachytherapy was found as effective as a longer regimen of low-dose-rate brachytherapy in localized prostate cancer.
Cabozantinib activated innate immunity and completely eradicated prostate cancer in a study using a mouse model.
Shorter course of higher dose radiation therapy provide effective treatment, costs less, and is easier on patients than current standard radiation therapy course.
There is no association between vasectomy and the risk of overall, high-grade, or advanced-stage prostate cancer or prostate cancer-related mortality.
A lower dose of abiraterone acetate with a low fat meal may have the same effect as taking the standard dose as recommended on an empty stomach.
Treatment expectations of individuals with metastatic prostate cancer and their health care providers often do not match.
African American men choosing active surveillance for their low-grade prostate cancer have overall poorer health than non-African American men undergoing active surveillance.
Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
A significant difference exists in the failure to follow-up rates among patients undergoing active surveillance at university-based hospitals versus safety-net hospitals.
The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.
A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.
Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.
A higher overall number of genetic alterations in cell-free circulating tumor DNA (ctDNA) were associated with worse treatment outcomes.
Investigators studied the effects of adding antiandrogen therapy to radiotherapy on cancer control and overall survival in men with prostate cancer recurrence after radical prostatectomy.
Clinicians May Want To Address Emotional Stress to Prevent Overtreatment of Localized Prostate Cancer
Some men with low-risk prostate cancer may opt for more aggressive treatments due to emotional distress.
The implementation of recommendations opposing regular prostate cancer screening appear to have lowered treatment rates dramatically.
Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.
This fact reviews how hormone therapy may be used to treat prostate cancer, treatment options for castration-resistant prostate cancer, and side effects of hormone therapy.
Patients on active surveillance with stable disease may be candidates for less intense surveillance
Although many men obtain a second opinion regarding their prostate cancer care options, they seldom deviate from the original course of action.
Magnetic resonance imaging and MRI-targeted biopsy can facilitate detection of clinically significant prostate disease.
Advanced prostate cancer is associated with substantial psychosocial morbidity; therefore, this study was conducted to evaluate whether mindfulness-based cognitive therapy reduces distress in this population.
Consensus statement presents guidelines for prostate magnetic resonance imaging (MRI) in patients with negative biopsy.
Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
[Clinical Medicine Insights: Oncology] This research examines the various mechanisms of resistance to chemotherapy in metastatic CRPC and the potential role of emerging regimens and agents in varying clinical phases of development.
Studies show better physical function and quality of life for cancer patients who do strength training or aerobic activity.
The impact of additional opinions on patient decision-making is limited.
Researchers report on their evaluation of the impact of the 2012 USPSTF recommendation on volumes of prostate biopsy and radical prostatectomy.
Researchers analyzed data from the NPCR of Sweden to determine whether more US men with prostate cancer would choose active surveillance if it were presented as a treatment option.
Safety of the smokeless tobacco product called into question after a study links it to increased prostate cancer mortality.
Growing evidence suggests a link between androgen deprivation therapy (ADT) and cognitive dysfunction, but whether it may contribute to the risk of dementia more broadly is unclear. In this study, researchers examined the association of ADT with subsequent development of dementia in patients with prostate cancer.
Radiotherapy administered postoperatively within 1 year of radical prostatectomy was associated with worse functional outcomes compared with radiotherapy administered 1 year or more after surgery.
Side effects experienced with extremely hypofractionated treatment for intermediate-risk prostate cancer were comparable to those of conventional radiation therapy at 2 years after treatment.
Prostate cancer survivors who maintain or begin recreational physical activity following cancer diagnosis report substantially higher quality of life than those who never exercise or stopped exercising after diagnosis.
Disease-specific mortality rates for men with prostate cancer are comparable for 3 treatment options: active surveillance, radical prostatectomy, and external-beam radiotherapy.
Despite that most patients with newly diagnosed prostate cancer receive high-quality care, a racial disparity exists, a recent study has shown.
The long-term use of androgen deprivation therapy (ADT) for up to 36 months does not appear to be associated with cognitive decline in patients with prostate cancer.
Following the USPSTF recommendation against routine PSA testing in all men, incidence rates of early stage prostate cancer in men 50 years and older declined substantially, according to a recent study.
Emotional distress is associated with an increased likelihood of opting for surgery among men with localized prostate cancer.
Race is not associated with the development of metastases in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to a recently published study.
Ethnicity influences patient decision to pursue active treatment and serial biopsies in active surveillance
Use of androgen suppression therapy may negatively impact survival in African American patients with favorable-risk prostate cancer.
Despite previous research demonstrating that the use of PDE-5 inhibitors such as sildenafil, tadalafil, and vardenafil may reduce the risk for developing prostate cancer, a new study suggests that these agents do not prevent prostate cancer.
As salvage radiotherapy (SRT) outcomes may be affected by factors associated with prostatectomy findings, they may be positively affected when used at lower prostate-specific antigen (PSA) levels.
Choosing no treatment and regular check-ups didn't seem to stress men with low-risk disease
Using an online decision-support tool led to most men with low-risk prostate cancer choosing active surveillance with less conflict about their decision.
Researchers in Sweden have, for the first time, estimated the risk of developing various types of prostate cancer for men with brothers and/or fathers with the disease.
Analysis of proteins identified in urine has led to the discovery of proteomic signatures for prostate cancer that have the potential to serve as highly accurate noninvasive biomarkers that can identify aggressive disease before surgery.
Functional status, a person's ability to perform normal activities of daily living, is associated with treatment choice for patients with prostate cancer.
Consumption of tree nuts is associated with lower mortality rates among men with prostate cancer. It did not, however, correlate with a reduced risk of developing prostate cancer.
Prostate-specific molecular imaging at initial biopsy and preoperative planning can accurately determine and delineate the extent of prostate cancer. The imaging technique was a type of PET/CT called 68Ga-PSMA PET/CT.
Laser heat may soon be an option to treat prostate cancer. Focal laser ablation has been found both feasible and safe in men with intermediate risk prostate cancer.
Screening PSA levels at midlife could identify men who are at greater risk of developing prostate cancer later in life and who should be monitored more closely.
Castration-resistant prostate cancer (CRPC) has specific metabolic characteristics that could make it susceptible to new options for treatment.
PSA levels in midlife strongly predict future lethal prostate cancer risk in U.S. cohort.
Physical exercise may have a direct effect on cancer that is as effective as drugs for treating patients with prostate cancer, even for those with advanced stages of the disease.
Length of stay (LOS) and blood loss were reduced with RARP compared with open radical prostatectomy in obese men with prostate cancer who underwent surgery for their disease.
Radiation therapy delivered to the critical vessels surrounding the prostate can result in erectile dysfunction and bladder and renal irritation. Vessel-sparing radiation and an improved understanding of the anatomy of the prostate can reduce these effects.
New research results favor testing for prostate specific antigen (PSA) levels for detection of prostate cancer. PSA tests can reduce the number of fatal cases of prostate cancer by detecting disease early.
Genetic Biomarker Predictive of Peripheral Neuropathy in Patients Receiving Docetaxel for Prostate Cancer
Docetaxel-induced neuropathy may be predicted by single nucleotide polymorphisms in VAC14.
Radiotherapy in combination with anti-androgen hormone therapy halves the risk of death from prostate cancer 15 years after diagnosis compared with hormone therapy alone.
The second-generation hsp90 inhibitor onalespib may be beneficial for men with prostate cancer that no longer responds to androgen deprivation therapy
Research also suggests that statins may help counteract harmful effect of fatty foods
A moderate to high level of physical activity before and after diagnosis may improve prognosis in patients with non-metastatic prostate cancer.
Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate Cancer
Treatment with a hypofractionated radiotherapy (HRT) schedule achieved similar efficacy as treatment with the longer, conventional RT (CRT) schedule in men with low-risk prostate cancer.
A new urine assay that can detect genetic changes correlated with prostate cancer correctly identified cancer grade in 92% of men with elevated PSA levels and high-grade cancers.
Researchers found that men with prostate cancer who had exercised regularly had the best outcomes.
New technology has enabled doctors to administer higher doses of radiation to prostate cancer tumors with fewer side effects; however, escalating the dose of radiation may not help patients with localized prostate cancer in the long term.
Site of metastasis is key to the length of time a patient can survive metastatic castration-resistant prostate cancer (mCRPC).
Men age 67 years or older with prostate cancer were 37% more likely to be hospitalized for noncancer reasons after their cancer diagnosis than before their diagnosis.
Radiation doses to the bladder and rectum were reduced with intensity-modulated radiotherapy (IMRT) for prostate cancer.
Higher Treatment Volumes at Radiation Facilities Lead to Improved Overall Survival in Prostate Cancer
Among men with aggressive prostate cancer, overall survival (OS) rates improve when they receive radiation treatment at facilities that frequently perform the treatment.
The combination of bicalutamide and everolimus may be effective in men with bicalutamide-naïve castration-resistant prostate cancer (CRPC).
A complex surgical procedure to remove the prostate achieves excellent long-term survival for men with prostate cancer after radiation therapy has failed.
Although reported absolute rates of second malignancies after radiotherapy for prostate cancer are very low, it is associated with higher rates of bladder, colon, and rectal cancers in patients who undergo radiotherapy for prostate cancer.
Both insufficiency and deficiency of serum vitamin D correlated with an increased risk of unfavorable pathology in men undergoing radical prostatectomy for prostate cancer.
Patients with slow-growing prostate cancer are increasingly opting for active surveillance and only changing treatment plan if the disease changes to a higher risk form to avoid unnecessary and potentially toxic treatments.
Adding 6 months of adjuvant androgen suppression to radiotherapy improves biochemical and clinical disease-free survival (DFS).
The use of proton therapy to treat patients with prostate cancer increased more than 2-fold from 2004 to 2012.
Overall survival (OS) is worse for men with castration-resistant prostate cancer (CRPC) metastases to the lung and liver.
Very few older man receive the intensity of active surveillance testing recommended by major prospective active surveillance (AS) programs.
Recent developments in a gas chromatography tool might allow doctors to determine whether urologic cancers are present via a urine sample.
The risk for developing colorectal cancer is increased after a diagnosis of prostate cancer.
Radium-223 dichloride (radium-223) improves overall survival in patients with castration-resistant prostate cancer (CRPC).
Survivors of prostate cancer should be made aware of an increased risk for heart disease. It is the most common noncancer cause of death for men with prostate cancer.
The growth of castration-resistant prostate cancer cells was reduced by a first-in-class sphingosine kinase 2 inhibitor, but the cells were not killed.
Men with prostate cancer and bone metastases that have experienced at least one skeletal-related event (SRE) show worse survival, according to a recent study.
Positron emission tomography (PET) imaging may offer a superior method of imaging for metastatic prostate cancer.
This fact sheet reviews the PSA test for prostate cancer, in particular screening recommendations, test limitations, and possible improvements the future may hold in store for the test.
Among persons 65 years or older with limited life expectancies of less than 10 years, an estimated 15.7% may have undergone nonrecommended screenings for prostate and breast cancers.
Enzalutamide significantly reduced the risk of prostate cancer progression or death in prostate cancer.
Phase 3 results of the TRAPEZE trial of patients with bony metastatic castrate-refractory prostate cancer (CRPC).
The risk of lethal prostate cancer, but not of overall, high-grade, or advanced cancers, was reduced with regular aspirin use.
Novel Diagnostic Test Uses CTCs in Blood to Guide Treatment Decisions for Patients With Prostate Cancer
An experimental liquid biopsy using a blood sample may determine which patients with prostate cancer will benefit from hormone therapies.
Important discussions about prostate cancer screening and treatment are not occurring between men and their health care team.
A total of 40% of patients with mCRPC treated with docetaxel after abiraterone achieved at least a 50% reduction in PSA, according to a study presented at the 2016 Genitourinary Cancers Symposium.
African American men with Gleason score 3+3=6 prostate cancer produce less PSA and have significantly lower PSA density than white men, according to a new study. These findings could have important implications for treatment decision-making.
Risks of Adverse Effects Lower With Surgical Castration Vs. Chemical Castration for Metastatic Prostate Cancer
Surgical castration via orchiectomy for metastatic prostate cancer is associated with lower risks for adverse effects compared with medical castration via GnRHa therapy.
Twins carry a significant excess familial risk for cancer overall and for specific types of cancer, including prostate, melanoma, breast, ovary, and uterus, according to a long-term follow-up study of twins in Nordic countries.
Gonadotropin-releasing hormone agonist (GnRHa) therapy is associated with increased risks of numerous clinically relevant adverse events compared with orchiectomy.
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including Informal Caregivers of Elderly in Discharge Process Reduces Readmission Risk
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- CQGS Releases Standards for Surgical Care of Older Adults
- Radiation Protocol Deviations Linked to Worse Outcomes in Pediatric Brain Malignancy
- Use of Counseling, Surgery Rates Show Limited Physician Knowledge of Breast Cancer Genetic Testing
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|